RPL37P21

Across TCGA pan-cancer cohorts, RPL37P21 RNA is linked to patient survival in 7 of 34 cancer types, making it the most broadly survival-associated RPL37P21 data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPL37P21 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL37P21 expression acts as an unfavorable survival marker.

OV, PAAD, and UCEC are the cancer types where RPL37P21 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Tertile	II,III,IV	0.208	0.845	<.001	108	view →
PAAD	OS	Tertile	All	0.094	0.640	<.001	72	view →
UCEC	OS	Tertile	II,III,IV	0.293	0.771	.003	72	view →
SARC	DFS	Tertile	All	0.157	0.616	<.001	36	view →
KICH	OS	Tertile	II,III,IV	0.155	0.880	<.001	27	view →
STAD	OS	Tertile	IV	0.075	0.496	.013	27	view →
BLCA	DFS	Tertile	III,IV	0.159	0.572	.036	9	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

RPL37P21–OV (OS)

Open the OV breakdown →